Skip to content
Log in
Sponsored Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt
Open access

Real‐World Characteristics and Early Outcomes of Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma

T. Tsujino K. Tamura R. Taoka M. Miyake K. Kobayashi Y. Sasaki K. Ogawa S. Tatarano S. Katayama M. Kato Y. Abe Y. Oda K. Wada Junya Furukawa M. Araki H. Enokida Koji Shiraishi K. Inoue T. Inamoto Haruhito Azuma
Oct 2026 · International journal of urology · Vol 33 · 0 citations · 15 references
Medicine

TL;DR

Enfortumab vedotin plus pembrolizumab (EV) plus pembrolizumab (EVP) has become a standard first‐line regimen for unresectable locally advanced or metastatic urothelial carcinoma.

Abstract

Enfortumab vedotin (EV) plus pembrolizumab (EVP) has become a standard first‐line regimen for unresectable locally advanced or metastatic urothelial carcinoma. Further characterization of clinical heterogeneity and toxicity may complement existing Japanese real‐world data.

DOI PubMed Semantic Scholar
Read PDF

Similar papers

Open access Oct 2026

Quantitative Evaluation of Pharmacologic Synergy for Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle‐Invasive Bladder Cancer: A Copula‐Based Secondary Analysis

Perioperative treatment with enfortumab vedotin (EV) plus pembrolizumab has demonstrated a high pathological complete response (pCR) rate in patients with cisplatin‐ineligible muscle‐invasive bladder cancer (MIBC). However, whether this therapeutic benefit reflects true pharmacologic synergy or can be explained by inde...

Riko Ikeda, Soichiro Yoshida, Wei Chen et al. · 1 citation
Oct 2026

Interpreting International Real‐World Survival Outcomes After Avelumab First‐Line Maintenance in Advanced Urothelial Carcinoma: An RMST Analysis of Reconstructed Individual Patient Data

Avelumab first‐line maintenance is an established treatment strategy for patients with advanced or metastatic urothelial carcinoma without progression after platinum‐based chemotherapy. Overall survival outcomes reported in international real‐world cohorts are difficult to compare because of differences in patient back...

R. Kasahara, T. Ueki · 0 citations
Open access Oct 2026

Oncological Outcomes and Safety Profiles of Adjuvant Nivolumab in Muscle‐Invasive Urothelial Carcinoma

Perioperative immunotherapy has become the standard of care in patients with high‐risk muscle‐invasive urothelial carcinoma (MIUC). This study aimed to clarify oncological outcomes and safety profiles of adjuvant nivolumab therapy in MIUC, focusing on upper tract urothelial carcinoma (UTUC).

Satoshi Katayama, Tatsushi Kawada, K. Mori et al. · 1 citation
Open access Oct 2026

Skin Toxic Effects and Survival With Enfortumab Vedotin–Pembrolizumab in Advanced Urothelial Carcinoma

It is suggested that treatment-emergent skin toxic effects may serve as an early clinical marker of treatment benefit in patients receiving first-line enfortumab vedotin plus pembrolizumab and warrant prospective validation.

Zachariah Thomas, Cindy Y. Jiang, Patrick Speck et al. · 0 citations
Nov 2026

Location, Location, Location: Membranous Nectin-4 as a Biomarker for Enfortumab Vedotin.

Combination therapy with enfortumab vedotin, a Nectin-4-targeted antibody-drug conjugate, and pembrolizumab, an anti-PD1 antibody, recently supplanted platinum-based chemotherapy as standard first-line systemic therapy for patients with muscle-invasive or metastatic urothelial cancer. A composite biomarker integrating...

James A. Rodrigues, H. Al-Ahmadie, D. Aggen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.